Compare JJSF & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | NUVB |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | 1800 | 291 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1995 | N/A |
| Metric | JJSF | NUVB |
|---|---|---|
| Price | $82.54 | $4.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $140.00 | $11.22 |
| AVG Volume (30 Days) | 193.4K | ★ 4.8M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | $0.87 | $182.76 |
| Revenue Next Year | $1.88 | $91.83 |
| P/E Ratio | $1,645.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $80.00 | $1.57 |
| 52 Week High | $142.69 | $9.75 |
| Indicator | JJSF | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 35.18 |
| Support Level | $80.83 | $4.04 |
| Resistance Level | $87.73 | $5.73 |
| Average True Range (ATR) | 2.39 | 0.31 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 20.12 | 17.82 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.